Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics announced that it has executed a definitive contract manufacturing agreement worth approximately KRW 211.5B with Kiniksa Pharmaceuticals (UK), Ltd.
📊 [Key Disclosure Details & Summary Statistics]
- Contract Classification: Sales/Supply Contract (Contract Manufacturing Agreement for Pharmaceutical Products)
- Contract Amount: KRW 211,468,250,378 (KRW ~211.5B) / USD 152,168,274
- Recent Annual Revenue: KRW 3,694,588,767,068 (Based on 2023 consolidated financial statements)
- Contract Ratio to Revenue: 5.72%
- Large Corporation Status: Applicable
- Counterparty: Kiniksa Pharmaceuticals (UK), Ltd
- Contract Period: June 21, 2024 – December 31, 2031
- Contract (Order) Date: June 25, 2024
- Non-disclosure Details: Not Applicable (Counterparty and terms disclosed immediately)
- Other Key Investment Matters:
- The contract amount was converted using the initial FX rate of USD/KRW 1,389.70 on June 25, 2024, based on the confirmed amount of USD 152,168,274.
- This contract represents the execution of the definitive main contract following the previous LOI disclosure (‘Major Management Matters’) filed on May 30, 2023.
- The contract end date is subject to change based on mutual agreement between both parties.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Main Contract Terms and Order Backlog Status in Periodic Reports
This disclosure marks the transition of a previously signed letter of intent (LOI) into a definitive main contract valued at approximately KRW 211.5B. Reviewing any changes in contract terms or amounts compared to the initial LOI, as well as potential future adjustments to the contract amount or period, is important for understanding how this order translates into realized revenue. Relevant updates and order details can be verified in subsequent disclosures or periodic reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided strictly for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
